Brief: Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
05/02/2025 12:46
Feb 5 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON NEUROSCIENCE APPOINTS VALIDCARE AS CRO FOR ITS
PHASE 2A
DMT HUMAN STROKE TRIAL AND ANNOUNCES VALIDCARE’S USD $170K
EQUITY INVESTMENT
Source text: ID:nGNXb17RJP
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement